Analyst Price Target is C$3.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for 45525 (CUR.TO) in the last 3 months. The average price target is C$3.00, with a high forecast of C$3.00 and a low forecast of C$3.00. The average price target represents a ∞ upside from the last price of C$0.00.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in 45525 (CUR.TO). This Buy consensus rating has held steady for over two years.
9342-8530 Quebec Inc, formerly Diagnocure Inc, is a Canada-based biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml).
Read More